Kolon TissueGene, Inc.

Languages

  • English
  • Korean
  • English
  • About
    • Overview
    • History
    • Management Team
    • Board of Directors
    • Advisory Boards
  • Technology
    • Overview
    • TG-C
    • Publications
  • Product Pipeline
    • Overview
    • Applications
  • Clinical Trials
  • IR
    • Stock Data
    • PR
    • IR Material
    • Disclosure
    • Analyst Report
  • Partnering/Alliances
  • Contact

Analyst Report

IR

IR

  • Stock Data
  • PR
  • IR Material
  • Disclosure
  • Analyst Report
First-in-Class 도약 목표

First-in-Class 도약 목표

Nov 22, 2018

Company: 현대차증권
Analyst: 강양구

6,500억 규모 기술 추출로 명예회복

6,500억 규모 기술 추출로 명예회복

Nov 20, 2018

Company: NH 투자증권
Analyst: 구완성

산업분석 In-Depth 제약 바이오

산업분석 In-Depth 제약 바이오

Aug 31, 2018

Analyst: 진홍국

티슈진(950160.KQ)

티슈진(950160.KQ)

Dec 13, 2017

Company: 신영증권
Analyst: 엄여진

Coming Soon!

Coming Soon!

Nov 6, 2017

Company: 신영증권
Analyst: 엄여진

주사 한방으로 Global Unmet Needs 공략

주사 한방으로 Global Unmet Needs 공략

Oct 16, 2017

Company: 메리츠 종금증권
Analyst: 이태영

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

Oct 13, 2017

Company: 미래에셋대우
Analyst: 김태희

Kolon TissueGene, Aiming for DMOAD Designation

Kolon TissueGene, Aiming for DMOAD Designation

Oct 13, 2017

Company: Mirae Asset
Analyst: Taehee Kim

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

DMOAD (골관절염 근본적 치료제) 획득을 향한 도전

Oct 12, 2017

Company: 미래에셋대우
Analyst: 김태희

Kolon TissueGene, Invossa Could Be Osteoarthritis Game-Changer

Kolon TissueGene, Invossa Could Be Osteoarthritis Game-Changer

Sep 26, 2017

Company: Samsung Securities
Analyst: Brian Lee

© 2023 Kolon TissueGene, Inc. All Rights Reserved.

This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.

Privacy Policy Disclaimer Sitemap Ethical Management